Aronoff S C, Jacobs M R, Johenning S, Yamabe S
Antimicrob Agents Chemother. 1984 Oct;26(4):580-2. doi: 10.1128/AAC.26.4.580.
YTR 830, a new beta-lactamase inhibitor, was compared with clavulanic acid and sulbactam against aminopenicillin-resistant clinical isolates. At a concentration of 8 micrograms/ml, YTR 830 was as effective as clavulanate or sulbactam in reducing the aminopenicillin MICs. Combined with amoxicillin, YTR 830 is a potentially useful agent for therapy of many bacterial infections.
新型β-内酰胺酶抑制剂YTR 830与克拉维酸和舒巴坦针对耐氨基青霉素临床分离株进行了比较。在浓度为8微克/毫升时,YTR 830在降低氨基青霉素最低抑菌浓度方面与克拉维酸或舒巴坦效果相当。与阿莫西林联合使用时,YTR 830是治疗多种细菌感染的一种潜在有用药物。